Home » Stocks » MIST

Milestone Pharmaceuticals Inc. (MIST)

Stock Price: $7.67 USD 0.42 (5.79%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $7.79 +0.12 (1.57%) Jan 22, 5:59 PM
Market Cap 228.74M
Revenue (ttm) n/a
Net Income (ttm) -59.59M
Shares Out 29.77M
EPS (ttm) -2.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $7.67
Previous Close $7.25
Change ($) 0.42
Change (%) 5.79%
Day's Open 7.18
Day's Range 7.12 - 7.73
Day's Volume 107,610
52-Week Range 1.70 - 22.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 2 months ago

MONTREAL and CHARLOTTE, N.C., Nov. 23, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innov...

PRNewsWire - 2 months ago

MONTREAL and CHARLOTTE, N.C., Nov. 13, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innov...

PRNewsWire - 3 months ago

MONTREAL and CHARLOTTE, N.C., Oct. 23, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commer...

PRNewsWire - 3 months ago

MONTREAL and CHARLOTTE, N.C., Oct. 22, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commer...

PRNewsWire - 4 months ago

MONTREAL and CHARLOTTE, N.C., Sept. 22, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of inno...

InvestorPlace - 4 months ago

Milestone Pharmaceuticals offers a critical solution for those with an acute heart condition. However, it has a mixture of positives and negatives, making MIST stock a wild wager.

InvestorPlace - 5 months ago

When a biotech firm focuses its efforts on one disease and one drug, the stakes are high. Still, the payoff could be huge with MIST stock.

PRNewsWire - 5 months ago

MONTREAL and CHARLOTTE, N.C., Aug. 12, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc.

Zacks Investment Research - 5 months ago

Milestone Pharmaceuticals (MIST) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

InvestorPlace - 6 months ago

Milestone Pharmaceuticals (MIST) news for Thursday includes new guidelines for a clinical study pushing MIST stock higher.

24/7 Wall Street - 6 months ago

Milestone Pharmaceuticals Inc. (NASDAQ: MIST) shares more than doubled on Thursday after the company announced a key clinical and regulatory update.

PRNewsWire - 6 months ago

MONTREAL and CHARLOTTE, N.C., July 23, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc.

Zacks Investment Research - 7 months ago

As of late, it has definitely been a great time to be an investor in Milestone Pharmaceuticals.

Zacks Investment Research - 7 months ago

Milestone Pharmaceuticals (MIST) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor of Milestone Pharmaceuticals

Zacks Investment Research - 8 months ago

Top Ranked Momentum Stocks to Buy for May 19th

Other stocks mentioned: AGFS, SYRS, UNFI
PRNewsWire - 8 months ago

MONTREAL and CHARLOTTE, N.C., May 14, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innova...

Zacks Investment Research - 9 months ago

Milestone Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Zacks Investment Research - 9 months ago

Here we provide three stocks from the drug and biotech sector which can offer protection to an investor's portfolio amid stock market turmoil due to coronavirus crisis.

Other stocks mentioned: AMAG, CPIX
Benzinga - 10 months ago

Shares of small-cap Milestone Pharmaceuticals Inc (NASDAQ: MIST) were losing three-quarters of their value Tuesday on the back of a negative clinical readout.

The Motley Fool - 10 months ago

Soon-to-be-released pivotal clinical trial results could send this drug developer’s stock skyward.

About MIST

Milestone Pharmaceuticals, a biopharmaceutical company, develops and commercializes etripamil for the treatment of cardiovascular indications. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for the treatment of atrial fibrillation, angina, and other cardiovascular indications. The company was founded in 2003 and is headquartered in Montréal, Canada.

Industry
Biotechnology
Founded
2003
CEO
Joseph G. Oliveto
Employees
28
Stock Exchange
NASDAQ
Ticker Symbol
MIST
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for MIST stock is "Buy." The 12-month stock price forecast is 13.25, which is an increase of 72.75% from the latest price.

Price Target
$13.25
(72.75% upside)
Analyst Consensus: Buy